Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2016	Mar. 24, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	APVO
Entity Registrant Name	APTEVO THERAPEUTICS INC.
Entity Central Index Key	0001671584
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		20,918,290
Entity Public Float			$ 30.8

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 9,676	$ 4,637
Restricted cash	400
Short-term investments	44,849
Accounts receivable, net	4,284	6,456
Inventories	6,639	20,322
Income tax receivable, net		1,376
Prepaid expenses and other current assets	5,566	2,343
Total current assets	71,414	35,134
Property and equipment, net	5,910	4,179
In-process research and development		41,800
Intangible assets, net	14,534	17,441
Goodwill		29,213
Total assets	91,858	127,767
Current liabilities:
Accounts payable and other accrued liabilities	11,489	10,084
Accrued compensation	4,009	3,334
Contingent consideration, current portion		444
Sales rebates and discounts	3,235	2,238
Deferred revenue, current portion	811	3,843
Total current liabilities	19,544	19,943
Deferred revenue, net of current portion	2,896	3,318
Long-term debt, net	18,383
Deferred income taxes		15,817
Other liabilities	469	71
Total liabilities	41,292	39,149
Stockholders' equity:
Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding
Common stock: $0.001 par value; 500,000,000 shares authorized; 20,271,737 and zero shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively	20
Additional paid-in capital	151,271
Accumulated other comprehensive income	(33)
Contribution receivable from former parent	(20,000)
Former parent investment in subsidiary		320,606
Accumulated deficit	(80,692)	(231,988)
Total stockholders' equity	50,566	88,618
Total liabilities and stockholders' equity	$ 91,858	$ 127,767

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,271,737	0
Common stock, shares outstanding	20,271,737	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product sales	$ 36,254	$ 27,947
Collaborations	180	5,654
Total revenues	36,434	33,601
Costs and expenses:
Cost of product sales	24,182	16,933
Research and development	29,518	34,726
Selling, general and administrative	38,666	43,042
Impairment of goodwill and intangible assets	71,013
Loss from operations	(126,945)	(61,100)
Other income (expense):
Other income (expense), net	(810)	(237)
Total other income (expense), net	(810)	(237)
Loss before income taxes	(127,755)	(61,337)
Benefit from income taxes	15,340	2,020
Net loss	$ (112,415)	$ (59,317)
Net loss per share - basic and diluted	$ (5.55)	$ (2.93)
Shares used to compute net loss per share - basic and diluted	20,239,160	20,229,849

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (112,415)	$ (59,317)
Other comprehensive loss:
Unrealized losses on available-for-sale investments, net	(33)
Total comprehensive loss	$ (112,448)	$ (59,317)

CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Operating Activities
Net loss	$ (112,415)	$ (59,317)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	3,809	1,107
Depreciation and amortization	3,362	2,907
Impairment of goodwill and intangible assets	71,013
Restricted cash	(400)
Income taxes	(15,817)	(1,361)
Provision for allowance for doubtful accounts	200	3,481
Change in fair value of contingent consideration	(444)	214
Changes in operating assets and liabilities:
Accounts receivable	1,972	3,884
Inventories	13,683	(2,697)
Income taxes	1,376	(66)
Prepaid expenses and other current assets	(3,223)	2,860
Accounts payable, accrued compensation and other liabilities	2,479	(2,384)
Sales rebates and discounts	997	(8)
Deferred revenue	(3,454)	2,620
Net cash used in operating activities	(36,862)	(48,760)
Investing Activities
Purchases of property and equipment	(2,512)	(1,527)
Purchases of investments	(44,882)
Net cash used in investing activities	(47,394)	(1,527)
Financing Activities
Common stock issued upon exercise of stock options	20
Common stock issued upon vesting of restricted stock units	18
Proceeds from long-term debt	20,000
Debt issuance costs	(1,962)
Transfer from former parent, prior to spin-off	71,219	52,220
Contingent consideration payments		(889)
Net cash provided by financing activities	89,295	51,331
Increase in cash and cash equivalents	5,039	1,044
Cash and cash equivalents at beginning of period	4,637	3,593
Cash and cash equivalents at end of period	9,676	$ 4,637
Supplemental disclosures:
Contribution receivable from former parent	20,000
Cash paid for interest	537
Cash paid for taxes	$ 162

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY - USD ($) $ in Thousands	Total	Common Stock	Former Parent Investment in Subsidiary	Additional Paid-In Capital	Accumulated Deficit	Contribution Receivable from Former Parent	Accumulated Other Comprehensive Loss
Balance at Dec. 31, 2014	$ 94,608
Net transfers from former parent	53,327		$ 53,327
Net loss	(59,317)				$ (59,317)
Balance at Dec. 31, 2015	88,618		320,606		(231,988)
Net loss	(12,890)
Balance at Mar. 31, 2016	89,862
Balance at Dec. 31, 2015	88,618		320,606		(231,988)
Capitalization upon spinoff	20	$ 20
Capitalization upon spinoff (in shares)		20,229,849
Net transfers from former parent	70,529		(288,883)	$ 147,424	231,988	$ (20,000)
Unrealized losses on available-for-sale investments	(33)						$ (33)
Common stock issued upon exercise of stock options	20			20
Common stock issued upon exercise of stock options (in shares)		9,144
Common stock issued upon vesting of restricted stock units	18			18
Common stock issued upon vesting of restricted stock units (in shares)		32,744
Stock-based compensation	3,809			3,809
Net loss	(112,415)		$ (31,723)		(80,692)
Balance at Dec. 31, 2016	50,566	$ 20		$ 151,271	$ (80,692)	$ (20,000)	$ (33)
Balance (in shares) at Dec. 31, 2016		20,271,737
Balance at Mar. 31, 2016	89,862
Net loss	(12,838)
Balance at Jun. 30, 2016	$ 97,197

Nature of Business and Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Nature of Business and Significant Accounting Policies

Note 1. Nature of Business and Significant Accounting Policies

Organization and Basis of Presentation

Aptevo Therapeutics Inc., Aptevo or the Company, is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. On August 1, 2016 the Company became an independent publicly traded company through a pro-rata distribution of Aptevo’s common stock to Emergent BioSolutions Inc. (Emergent or Former Parent) stockholders. Each Emergent stockholder of record as of the close of business on August 1, 2016 received one share of Aptevo common stock for every two shares of Emergent common stock held on the record date. Aptevo’s common stock began “regular way” trading on the NASDAQ global stock market under the ticker symbol “APVO” on August 1, 2016.

In connection with the spin-off, on August 1, 2016, Aptevo and Emergent entered into a separation and distribution agreement as well as various other related agreements (collectively the Agreements) that govern the separation and the relationships between the parties going forward, including a transition services agreement, a manufacturing services agreement, an employee matters agreement, and a tax matters agreement. Prior to the separation, Aptevo was dependent upon Emergent for all of its working capital and financing requirements.

At the closing of the spin-off Aptevo recorded a contribution from Emergent of $71.2 million. This contribution included a one-time payment of $45.0 million, and a working capital reimbursement for outstanding payments of $1.4 million, which we received in the fourth quarter of 2016, a noncash transfer of an intangible asset of $0.7 million, and a net transfer of cash from Emergent of $24.2 million. Also recorded was a promissory note to receive $20.0 million from Emergent, which was received in the first quarter of 2017. In addition, on August 4, 2016, we entered into a $35.0 million Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust. The Credit Agreement provides us with up to $35.0 million of available borrowing capacity, which will be available (subject to certain conditions) to us in two tranches of $20.0 million and $15.0 million, respectively, through August 31, 2017. See Note 10 — Debt.

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles or GAAP.

Prior to August 1, 2016, the consolidated financial statements were prepared on a “carve-out” basis for the purpose of presenting Aptevo’s financial position, results of operations, and cash flows, and were derived from Emergent’s consolidated financial statements and accounting records. Aptevo did not operate as a standalone entity in the past and accordingly the selected financial data presented herein is not necessarily indicative of Aptevo’s future performance and does not reflect what Aptevo’s performance would have been had Aptevo operated as an independent publicly-traded company prior to August 1, 2016. The consolidated financial statements reflect Aptevo’s financial position, results of operations, and cash flows as a separately operated business in conformity with GAAP post the August 1, 2016 spin-off.

Prior to August 1, 2016, the consolidated financial statements included an allocation of certain assets and liabilities that have historically been held at the Emergent corporate level but which were specifically identifiable or allocable to Aptevo. All Aptevo intracompany transactions and accounts have been eliminated. All intercompany transactions between Aptevo and Emergent are considered to be effectively settled in the consolidated financial statements at the time the transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the consolidated statement of cash flows as a financing activity and in the consolidated balance sheet as a net investment from Emergent. As of August 1, 2016, in connection with the separation and distribution, Emergent’s investment in the Company’s business was redesignated as stockholder’s equity and allocated between common stock and additional paid-in capital based on the number of shares issued at the distribution date.

Prior to August 1, 2016, Aptevo’s consolidated financial statements included an allocation of expenses related to certain Emergent corporate functions, including senior management, legal, human resources, finance, information technology, and quality assurance. These expenses were allocated to Aptevo based on direct usage or benefit where identifiable, with the remainder allocated on a pro rata basis of expenses, headcount, square footage, or other measures. Aptevo considers the expense allocation methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had Aptevo operated as an independent, publicly-traded company for the periods presented.

Prior to August 1, 2016, the income tax amounts in these consolidated financial statements were calculated based on a separate return methodology and presented as if Aptevo’s operations were a standalone taxpayer in each of its tax jurisdictions.

Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation

The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries: Aptevo Research and Development LLC; Aptevo BioTherapeutics, LLC; and Aptevo Europe Limited. All intercompany balances and transactions have been eliminated.

The majority of our transactions occur in U.S. dollars, however we do have an agreement with Emergent for sales to two Canadian distributors. These sales are translated into U.S. dollars, the reporting currency, at the exchange rate prevailing at the balance sheet date.

Cash Equivalents

Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and include time deposits and investments in money market funds with commercial banks and financial institutions. In addition, was have restricted cash in the amount of $0.4 million maintained in depository as collateral for corporate credit cards.

Short-Term Investments

Short-term investments are classified as available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported as a component of comprehensive loss. Amortization, accretion, interest and dividends, realized gains and losses and declines in value judged to be other-than-temporary are included in other income (expense). The cost of securities sold is based on the specific-identification method. Investments in securities with maturities of less than one year, or those for which management intends to use the investments to fund current operations, are included in current assets. We evaluate whether an investment is other-than-temporarily impaired based on the specific facts and circumstances. Factors that are considered in determining whether an other-than-temporary decline in value has occurred include: the market value of the security in relation to its cost basis; the financial condition of the investee; and the intent and ability to retain the investment for a sufficient period of time to allow for recovery in the market value of the investment.

Concentrations of Credit Risk

Financial instruments that potentially subject Aptevo to concentrations of credit risk consist primarily of cash and cash equivalents, certain investments and accounts receivable. Aptevo places its cash and cash equivalents with high quality financial institutions and may maintain cash balances in excess of insured limits. Management believes that the financial risks associated with its cash and cash equivalents are minimal.

Accounts Receivable

Aptevo records accounts receivable net of an allowance for doubtful accounts based upon its assessment of collectability, and of applicable discounts. Aptevo performs ongoing credit evaluations of its customers and generally does not require collateral. At December 31, 2016 and December 31, 2015, we had an allowance for doubtful accounts balance of $3.3 million and $3.5 million, respectively.

Inventories

Inventories, including purchased inventories, are stated at the lower of cost or market with cost being determined using a moving average cost method, which approximates weighted-average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses (including allocation of fixed production-overhead costs) and includes the services and products of third-party suppliers. Aptevo analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. Aptevo also writes off, in the applicable period, the costs related to expired inventory and unsuccessful manufacturing runs.

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Furniture and equipment	7-10 years
Software and hardware	3-5 years or product life
Leasehold improvements	Lesser of the asset life or the remaining lease term

Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.

In-Process Research and Development and Long-lived Assets

Aptevo assesses in process research and development (IPR&D) and long lived assets for impairment on an annual basis or more frequently if indicators of impairment are present. Aptevo’s annual assessment includes a comparison of the fair value of IPR&D assets to existing carrying value, and recognizes an impairment when the carrying value is greater than the determined fair value. Aptevo believes that the assumptions used in valuing the intangible and IPR&D assets are reasonable and are based upon its best estimate of likely outcomes of sales and clinical development. The underlying assumptions and estimates used to value these assets are subject to change in the future, and actual results may differ significantly from the assumptions and estimates. Aptevo has selected October 1 as its annual impairment test date for indefinite-lived intangible assets.

Aptevo assesses the recoverability of its long-lived assets or asset groups for which an indicator of impairment exists by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If Aptevo concludes that the carrying value will not be recovered, Aptevo measures the amount of such impairment by comparing the fair value to the carrying value of the assets or asset groups. See Note 8 — Impairment of Intangible Assets, In-Process Research and Development and Goodwill.

Goodwill

Aptevo assesses the carrying value of goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. Aptevo utilizes either: (1) a two-step impairment test, which is a quantitative analysis, or (2) a step zero test, which is a qualitative analysis.

A two-step test would first compare Aptevo’s fair value to its carrying value. If the carrying value exceeds its fair value, then the second step of the impairment test is performed in order to determine the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, an impairment loss is recognized.

We generally base our measurement of fair value on a blended analysis of the present value of future discounted cash flows and market valuation approach. The discounted cash flows model indicates the fair value based on the present value of the cash flows that we expect to generate in the future. Our significant estimates in the discounted cash flows model include: our weighted average cost of capital; long-term rate of growth and profitability of our business; and working capital effects. The market valuation approach indicates the fair value of the business based on a comparison of the Company to comparable publicly traded firms in similar lines of business. Our significant estimates in the market approach model include identifying similar companies with comparable business factors such as size, growth, profitability, risk and return on investment and assessing comparable revenue and operating income multiples in estimating fair value.

If Aptevo is not required to do a quantitative analysis, it will evaluate goodwill using the qualitative assessment method, which permits companies to qualitatively assess whether it is more-likely-than-not that the fair value is less than its carrying amount. Aptevo considers developments in its operations, the industry in which it operates and overall macroeconomic factors that could have affected fair value since the date of the most recent quantitative analysis of fair value.

The determination of the fair value of is judgmental in nature and involves the use of significant estimates and assumptions. The estimates and assumptions used in calculating fair value include identifying future cash flows, which requires that Aptevo make a number of critical legal, economic, market and business assumptions that reflect best estimates as of the testing date. Aptevo’s assumptions and estimates may differ significantly from actual results, or circumstances could change that would cause Aptevo to conclude that an impairment now exists or that it previously understated the extent of impairment. See Note 8 — Impairment of Intangible Assets, In-Process Research and Development and Goodwill.

Contingent Consideration

Aptevo records contingent consideration associated with sales-based royalties at fair value. The fair value model used to calculate this obligation is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales and achievement of the milestones. The inputs Aptevo uses for determining the fair value of the contingent consideration associated with sales based royalties are Level 3 fair value measurements. Aptevo re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales. Any future increase in the fair value of the contingent consideration associated with sales based royalties are based on an increased likelihood that the underlying net sales will be achieved.

The associated payment or payments which will therefore become due and payable for sales based royalties will result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of contingent consideration associated with sales based royalties will result in a reduction in cost of product sales.

Fair Value of Financial Instruments

The Company measures and records cash equivalents and investment securities considered available-for-sale at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The carrying amounts of the Company’s short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair value due to their short maturities.

Sales Rebates and other Discounts

Aptevo markets and sells its products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost (WAC). Additionally, Aptevo may enter into separate agreements with indirect customers to acquire its products for a contracted price that is less than the product’s WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, continue to purchase Aptevo’s products from the wholesalers, but at their respective contractual prices. Per its wholesaler agreements, Aptevo guarantees to credit the wholesaler for the difference between the WAC and the indirect customers’ contracted price. This credit is referred to as a chargeback and revenues from product sales are recorded net of estimated chargebacks. Adjustments to the chargeback provisions are made periodically to reflect new facts and circumstances, therefore historical experience may not be indicative of current and/or future results.

All revenues from product sales are also recorded net of applicable allowances for sales and government rebates, special promotional programs, and discounts. Management does not believe there to be a legal right of offset related to these allowances and the receivables from wholesalers; accordingly, allowances are classified as a current liability in the accompanying balance sheets These allowances are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels, contract terms, and actual discounts offered. In arriving at these estimates, Aptevo further utilizes information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations.

Debt Issuance Costs

Aptevo defers costs related to debt issuance and amortize these cost to interest expense over the term of the debt, using the effective interest method. Debt issuance costs are presented in the balance sheet as a reduction of the carrying amount of the debt liability.

Revenue Recognition

Aptevo recognizes revenue if four basic criteria have been met: (1) there is persuasive evidence of an arrangement, (2) delivery has occurred or services have been rendered, (3) the fee is fixed or determinable, and (4) collectability is reasonably assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time as all criteria are met.

Collaborations

Revenue generating collaborative research and development agreements may contain one or more provisions including licensing, research services and milestone deliverables. Aptevo analyzes its multiple element revenue generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: (1) the delivered item(s) has value to the customer on a standalone basis, and (2) if the arrangement includes a general right of return and delivery, the performance of the undelivered item(s) is considered probable and substantially in the control of Aptevo. Items that cannot be divided into separate units are consolidated with other units of accounting, as appropriate. Consideration to be received is allocated among the separate units based on each unit’s relative selling price and is then recognized when the appropriate revenue recognition criteria are met. Aptevo deems services to be rendered if no continuing obligation exists on the part of Aptevo.

Revenue associated with non-refundable upfront license fees that can be treated as a single unit of accounting is recognized when all ongoing obligations have been delivered. Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue either on a straight-line basis over Aptevo’s continued involvement in the research and development process or based on the proportional performance of Aptevo’s expected future obligations under the contract.

Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved and the milestone payments are due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is non-refundable, (2) achievement of the milestone was not reasonably assured at the inception of the arrangement, (3) substantive effort is involved to achieve the milestone and (4) the amount of the milestone payment appears reasonable in relation to the effort expended. If not deemed substantive, Aptevo recognizes such milestone as revenue on a percent of completion basis over the remaining expected term of continued involvement in the research and development process. Payments received in advance of revenue recognized are recorded as deferred revenue.

Product Sales

The Company markets and sells its products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost (WAC). Additionally, the Company may enter into separate agreements with indirect customers to acquire its products for a contracted price that is less than the product’s WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, continue to purchase the Company’s products from the wholesalers, but at their respective contractual prices. Per its wholesaler agreements, the Company guarantees to credit the wholesaler for the difference between the WAC and the indirect customers’ contracted price. This credit is referred to as a chargeback and revenues from product sales are recorded net of estimated chargebacks. Adjustments to the chargeback provisions are made periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results.

All revenues from product sales are also recorded net of applicable allowances for sales and government rebates, special promotional programs, and discounts. These allowances are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels, contract terms, and actual discounts offered. In arriving at these estimates, the Company further utilizes information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations.

The Company defers the recognition of revenue from the sales of new product introductions until the commercial wholesalers resell the product to the healthcare providers. This is due to the inherent uncertainties in estimating normal wholesaler inventory levels of new products in addition to possible product launch incentives such as extended payment terms and expanded return rights that allow the wholesalers to return the product. Once the Company gains enough historical experience to reasonably estimate allowances for chargebacks, rebates and other discounts, revenue from sales and the related allowances are recognized upon sale to the wholesaler.

Research and Development

Research and development costs are expensed as incurred. Research and development costs primarily consist of internal labor costs, fees paid to outside service providers and the costs of materials used in clinical trials and research and development. Other research and development expenses include facility, maintenance and related support expenses.

A substantial portion of Aptevo’s pre-clinical studies and all of its clinical studies have been performed by third-party contract research organizations (CRO). The Company reviews the activities performed by the CROs each period. For pre-clinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical study expenses, the significant factors used in estimating accruals include the number of patients enrolled and percentage of work completed to date. The Company’s estimates are highly dependent upon the timeliness and accuracy of the data provided by its CRO’s regarding the status of each program and total program spending and adjustments are made when deemed necessary.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of personnel-related costs and professional fees in support of our executive, sales and marketing, business development, finance, accounting, information technology, legal and human resource functions. Other costs include facility costs not otherwise included in cost of product sales or research and development expense.

Stock-Based Compensation

Under the Financial Accounting Standards Board’s (FASB) ASC 718, Compensation—Stock Compensation, we measure and recognize compensation expense for restricted stock, restricted stock units (RSUs), and stock options granted to our employees and directors based on the fair value of the awards on the date of grant. The fair value of stock options is estimated at the date of grant using the Black-Scholes option pricing model that requires management to apply judgment and make estimates, including:

•

the expected term of the stock option award, which we calculate using the simplified method, as permitted by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment, as we have insufficient historical information regarding our stock options to provide a basis for an estimate;

•

the expected volatility of our underlying common stock, which we estimate based on the historical volatility of a representative group of publicly traded biopharmaceutical companies with similar characteristics to us, and our own historical and implied future volatility;

•

the risk-free interest rate, which we based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued;

•

the expected dividend yield, which we estimate to be zero based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends; and

•

the fair value of our common stock on the date of grant.

Stock-based compensation expense for RSUs is recognized on a straight-line basis over the vesting period of the respective award. Stock-based compensation expense for our stock options, both converted and Aptevo granted, is recognized on a straight-line basis over the vesting period of the respective award.

We are required to estimate a forfeiture rate to calculate the stock-based compensation expense for our awards. Our forfeiture rate for the converted RSUs and options is based on an analysis of the actual forfeitures experienced by Emergent. For the RSUs and options issued by Aptevo, we have estimated a forfeiture rate of ten-percent. Since inception our actual forfeiture rate has been de minimis. We routinely evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover, and expectations of future option exercise behavior.

Income Taxes

Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.

Aptevo’s ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. Aptevo considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if Aptevo determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, Aptevo will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to the provision for income taxes in the period in which the determination is made. Likewise, if Aptevo determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, Aptevo will establish a valuation allowance against deferred tax assets, with an offsetting increase to the provision for income taxes, in the period in which the determination is made.

Because tax laws are complex and subject to different interpretations, significant judgment is required. As a result, Aptevo makes certain estimates and assumptions, in (1) calculating Aptevo’s income tax expense, deferred tax assets and deferred tax liabilities, (2) determining any valuation allowance recorded against deferred tax assets and (3) evaluating the amount of unrecognized tax benefits, as well as the interest and penalties related to such uncertain tax positions. Aptevo’s estimates and assumptions may differ significantly from tax benefits ultimately realized.

Segment Reporting

The Company has determined that it operates in a single segment and has one reporting unit: the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.

New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. Aptevo is continuing to evaluate the effect that the standard will have on its consolidated financial statements and related disclosures including the areas of variable consideration and new disclosure requirements. Aptevo is currently expecting to use the modified retrospective method to adopt this standard.

In August 2014, the FASB issued ASU No.2014-15 Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under the new guidance, management is required to assess an entity’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. The provisions of this standard are effective for annual periods ending after December 31, 2016, and for annual and interim periods thereafter. We adopted this guidance for the year ended December 31, 2016 and management believes that our existing cash and cash equivalents will be sufficient to fund our operations through the first quarter of 2018.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short term leases) at the commencement date. Lessor accounting under ASU 2016-02 is largely unchanged. ASU 2016-02 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Under ASU 2016-02, lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Lessees and lessors may not apply a full retrospective transition approach. The Company has not yet selected an implementation date nor has it determined the effect of the standard on the Company’s ongoing financial reporting.

In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 simplifies the accounting for share-based payment award transactions including the financial statement presentation of excess tax benefits and deficiencies, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. Aptevo is currently evaluating the requirements of ASU 2016-09 and have not yet determined the impact on its consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,” which clarifies the classification and presentation of eight specific cash flow issues in the statement of cash flows. This standard is effective beginning January 1, 2018, with early adoption permitted. The new standard requires a retrospective transition. Aptevo is currently evaluating the impact of the new standard on its consolidated financial statements.

Restatement

12 Months Ended

Dec. 31, 2016

Accounting Changes And Error Corrections [Abstract]

Restatement

Note 2. Restatement

Restatement Background

Our December 31, 2015 financial statements include $41.8 million of intangible assets which resulted from the acquisition of IPR&D programs related to TRU-016, a novel CD37-directed therapy for B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. This amount was deemed to be an indefinite-lived asset, to remain as an indefinite-lived asset on the balance sheet until completion or abandonment of the associated research and development efforts. Following the spin-off of the Company in August 2016, the Company conducted an internal review of all deferred tax assets and liabilities acquired and it was determined that a deferred tax liability should have been recorded associated with the difference between the book basis and the tax basis of the asset as a part of the acquisition in 2010. The error has no effect on the net assets distributed in the spin-off.

Impact of Restatement on Consolidated Balance Sheets

The Company has restated its consolidated balance sheet as of December 31, 2015. The restatement resulted in an increase in deferred tax liabilities of $15.3 million and a corresponding $15.3 million increase in goodwill. The restatement had no impact on total stockholders’ equity.

The impact of the restatement on the Company’s consolidated balance sheets is reflected and quantified for 2015 in the below table.

Balance Sheet Impact:

⁽¹⁾


(in thousands)	December 31, 2015 (As previously reported)		Restatement Adjustment		December 31, 2015 (Restated)
Goodwill	$	13,902	$	15,311	$	29,213
Total assets		112,456		15,311		127,767

Deferred tax liability		506		15,311		15,817
Total liabilities	$	23,838	$	15,311	$	39,149
Total stockholders equity	$	88,618	$	—	$	88,618

See Note 17 for unaudited information on the impact of this restatement to unaudited interim periods.

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References + Details

MorphoSys Collaboration Agreement	12 Months Ended
MorphoSys Collaboration Agreement	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
MorphoSys Collaboration Agreement	Note 3. MorphoSys Collaboration Agreement In August 2014, Aptevo entered into a collaboration agreement with MorphoSys AG (MorphoSys Agreement) for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic protein, which activates host T-cell immunity specifically against cancer cells expressing prostate specific membrane antigen, an antigen commonly overexpressed on prostate cancer cells. MOR209/ES414 was constructed using Aptevo’s proprietary ADAPTIR™ platform technology. In accordance with the initial terms of the MorphoSys Agreement, Aptevo received a nonrefundable $20.0 million upfront payment and could receive up to $163.0 million in additional contingent payments, comprised of up to $80.0 million and up to $83.0 million, respectively, due upon the achievement of specified development and regulatory milestones. MorphoSys and Aptevo jointly agreed to fund further development of MOR209/ES414, with Aptevo responsible for 36% of the total development costs and MorphoSys responsible for the remainder, with Aptevo’s funding requirement capped at $186.0 million. Aptevo’s development effort includes the performance of non-clinical, clinical, manufacturing and regulatory activities. Aptevo retains commercialization rights in the U.S. and Canada, with a tiered royalty obligation to MorphoSys, ranging from mid-single digit up to 20% of sales. MorphoSys has worldwide commercialization rights excluding the U.S. and Canada, with a low single digit royalty obligation to Aptevo. In December 2015, after a joint review of data from the ongoing Phase 1 dose escalation study of MOR209/ES414 in prostate cancer patients, Aptevo and MorphoSys decided to adjust the dosing regimen and administration of MOR209/ES414. Patients receiving weekly doses of MOR209/ES414 developed antibodies against the drug; this is called anti-drug antibodies, or ADA. ADA developed in most patients including those receiving the maximum tolerated dose of drug which could be given safely on a weekly basis. These antibodies bind to the drug and reduce the concentration of active MOR209/ES414 in the blood and thus could potentially reduce its efficacy. However, no safety issues related to the development of ADA were observed. The cause of these antibodies is unclear but could be due to the weekly administration of the drug. Hence, the protocol was amended to a continuous intravenous infusion as a way to administer higher levels of drug and prevent the development of ADA. The MOR209/ES414 Phase I clinical trial under the amended protocol, providing continuous intravenous infusion as a way to administer higher levels of drug and prevent the development of ADA, commenced December 2016. As a result of the required dosing regimen change and the impact to the overall development timeline and technical risk, our co-development agreement with MorphoSys was restructured. In December 2015, Aptevo and MorphoSys amended the collaboration agreement to decrease the additional contingent payments due to Aptevo upon the achievement of specified development and regulatory milestones of up to $32.5 million and up to $41.5 million, respectively and change the total funding requirement cap for Aptevo to up to approximately $250.0 million. In December 2016, the collaboration agreement was further amended to adjust the allocation of certain manufacturing and development costs and extend MorphoSys’s convenience termination rights. Under the amendment, we will bear 75% of all development costs with respect to MOR209/ES414, and MorphoSys will bear 25% of such costs, during the period from January 1, 2017 through June 30, 2017. During the period from July 1, 2017 through December 31, 2018, we will bear 49% of such development costs and MorphoSys will bear 51%. Beyond January 1, 2019, we will bear 36% and MorphoSys will bear 64% of such development costs. In addition, the timeframe for a one-time right to terminate the collaboration agreement by MorphoSys has been extended from December 31, 2016 to June 30, 2017, or within one week following the receipt and discussion of clinical data from the first six patients enrolled and dosed in the MOR209/ES414 Phase I clinical trial. Aptevo evaluated the MorphoSys Agreement and determined that it was a revenue arrangement with multiple deliverables or performance obligations. Aptevo determined there were two units of accounting under the MorphoSys Agreement: (1) the delivered license to further develop and commercialize MOR209/ES414, and (2) undelivered items related to development services. Aptevo determined that the license had standalone value as the drug candidate has been: (1) developed and is currently Phase 1 clinical trial ready, (2) MorphoSys possesses the knowledge, technology, skills, experience and infrastructure necessary to complete all further development of the drug through commercialization, and (3) MorphoSys has the right to further sublicense the product. In 2014, Aptevo allocated the $20.0 million upfront payment to the two units of accounting using the relative selling price method. Aptevo determined the estimated selling price for the license using the income approach and an appropriate discount rate. The estimated selling price includes unobservable inputs (Level 3), such as estimates of revenues and operating margins; the time and resources needed to complete the development and approval of the product candidate; and the risk related to the viability of and potential for alternative treatments. Aptevo determined the estimated selling price of the development services unit of accounting based on the estimated number of full-time equivalent personnel at the contractual rate as defined in the MorphoSys Agreement, whose rates and terms approximate those of other Emergent or Aptevo service related contracts and those observed generally through other collaboration negotiations. The allocation resulted in $15.3 million of the $20.0 million upfront payment being allocated to the license and $4.7 million being allocated to the development services. Aptevo determined the license fee unit of accounting was delivered and completed on the date the MorphoSys Agreement was executed and thus recognized $15.3 million of license revenue in August 2014. Revenue related to the development services is recognized as the services are performed with $0.1 million and $0.5 million, respectively, recognized in the year ended December 31, 2016 and 2015. The current estimated service period for the undelivered development services under the MorphoSys Agreement is through 2023. Further, Aptevo determined that contingent payments for the achievement of the development and regulatory milestones are substantive milestones and will be accounted for as revenue in the period in which the milestones are achieved. Aptevo received a $5.0 million milestone payment from MorphoSys reflecting the initiation of a Phase I clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer. Aptevo recognized this substantive milestone achievement payment as research and development revenue during the six months ended June 30, 2015. The MorphoSys Agreement provides for the sharing of development and clinical costs related to MOR209/ES414. In the event Aptevo’s share of the total cost incurred for a given quarter exceeds its pro rata limit, Aptevo records a receivable from MorphoSys for the excess and reduces research and development expense by this amount. For the year ended December 31, 2016 Aptevo recorded a reduction to research and development expense of $0.1 million and for the year ended December 31, 2015 Aptevo recorded a reduction to research and development expense of $4.3 million. As of December 31, 2016, the MorphoSys Agreement related accounts receivable balance was $0.0 million and the related total deferred revenue balance was $3.7 million.

Fair Value Measurements

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4. Fair Value Measurements

The Company’s estimates of fair value for financial assets and financial liabilities are based on the framework established in the fair value accounting guidance. The framework is based on the inputs used in valuation, gives the highest priority to quoted prices in active markets and requires that observable inputs be used in the valuations when available. The disclosure of fair value estimates in the fair value accounting guidance hierarchy is based on whether the significant inputs into the valuation are observable. In determining the level of the hierarchy in which the estimate is disclosed, the highest priority is given to unadjusted quoted prices in active markets and the lowest priority to unobservable inputs that reflect the Company’s significant market assumptions. The level in the fair value hierarchy within which the fair value measurement is reported is based on the lowest level input that is significant to the measurement in its entirety. The three levels of the hierarchy are as follows:

Level 1— Quoted prices in active markets for identical assets and liabilities;

Level 2— Inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3— Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company held no financial assets measured at fair value as of December 31, 2015. The Company’s financial assets measured at fair value consisted of the following as of December 31, 2016:

	December 31, 2016
(in thousands)	Level 1		Level 2		Level 3		Total
Financial Assets:
Money market funds	$	5,215	$	—	$	—	$	5,215
Corporate bonds		—		9,951		—		9,951
US government and agency debt securities		—		34,898		—		34,898
Total assets	$	5,215	$	44,849	$	—	$	50,064

If quoted market prices in active markets for identical assets are not available to determine fair value, then the Company uses quoted prices of similar instruments and other significant inputs derived from observable market data obtained from third-party data providers. These investments are included in Level 2 and consist of debt securities of U.S government agencies and corporate bonds. There were no transfers between Levels 1 and 2 during the twelve-month period ended December 31, 2016.

The following table is a reconciliation of the beginning and ending balance of the liabilities (contingent consideration) measured at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2016. The royalty agreement associated with HepaGam B expired on June 30, 2016, and no future royalty payments are expected on sales after that date.

(in thousands)
Balance at December 31, 2015	$	444
Expense included in earnings		19
Settlements		(463	)
Balance at December 31, 2016	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investments

12 Months Ended

Dec. 31, 2016

Investments Debt And Equity Securities [Abstract]

Investments

Note 5. Investments

Investments are classified as available-for-sale securities and are carried at fair value with unrealized temporary holding gains and losses excluded from net income or loss and reported in other comprehensive income or loss and also as a net amount in accumulated other comprehensive income or loss until realized. Available-for-sale securities are written down to fair value through income whenever it is necessary to reflect other than temporary impairments. The Company determined that the unrealized gains on its marketable securities as of December 31, 2016 were temporary in nature, and the Company currently does not intend to sell these securities before recovery of their amortized cost basis. All short-term investments are limited to a final maturity of less than one year from the reporting date.

	December 31, 2016
(in thousands)	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding (Losses)			Estimated Fair Value
Cash equivalents:
Money market fund	$	5,215	$	—	$	—		$	5,215
Total cash equivalents	$	5,215	$	—	$	—		$	5,215

Short-term investments:
Corporate bonds	$	9,959	$	1	$	(9	)	$	9,951
US government and agency debt securities		34,923		—		(25	)		34,898
Total short-term investments	$	44,882	$	1	$	(34	)	$	44,849

Inventories

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventories

Note 6. Inventories

Inventories consist of the following:

	December 31,		December 31,
(in thousands)	2016		2015
Raw materials and supplies	$	260	$	6,520
Work-in-process		1,165		4,730
Finished goods		5,214		9,072
Total inventories	$	6,639	$	20,322

CMC ICOS Biologics, Inc., (CMC), is the exclusive manufacturer of bulk drug substance for the IXINITY product. During 2015, we ordered nine manufacturing lots of bulk drug substance from CMC and only one of those lots was successfully manufactured and released in 2015. On October 4, 2016, we provided a Notice of Interruption in Manufacturing, or Notice, to the FDA, notifying the FDA of a potential interruption in the supply of IXINITY® coagulation factor IX (recombinant) due to the ongoing manufacturing challenges with the manufacturer of the bulk drug. On March 15, 2017, we announced the successful manufacture of a recent bulk drug substance batch of IXINITY and we anticipate that the new supply will be available beginning in May 2017, after the completion of routine final drug product (FDP) manufacturing activities. While we do not currently anticipate or foresee a supply shortage or supply interruption occurring, any supply shortage or supply interruption of IXINITY would adversely affect its sales and could adversely affect its market position, commercial viability and the trading price of our common stock.

Due to the challenges with the manufacture of our IXINITY product that meets release specifications for the final drug product, we wrote off unsaleable IXINITY inventory that was in the process of being manufactured in the amount of $7.1 million in 2016. This cost is included in cost of product sales.

Property and Equipment, Net

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Property and Equipment, Net

Note 7. Property and equipment, net

Property, plant and equipment consist of the following:

	December 31,			December 31,
(in thousands)	2016			2015
Leasehold improvements	$	2,265		$	2,152
Furniture and equipment		10,283			7,884
Property and equipment, gross		12,548			10,036
Less: Accumulated depreciation		(6,638	)		(5,857	)
Total property and equipment, net	$	5,910		$	4,179

Impairment of Intangible Assets, In-Process Research and Development and Goodwill	12 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Impairment of Intangible Assets, In-Process Research and Development and Goodwill	Note 8. Impairment of Intangible Assets, In-Process Research and Development and Goodwill During the period between the spin off date and September 30, 2016, we experienced a significant decline in our stock price. Based on this, we concluded that a significant potential impairment indicator existed to require us to perform an interim assessment of goodwill and indefinite-lived intangible assets as of September 30, 2016. We performed an interim first step of our impairment assessment and determined there was a potential impairment of goodwill and indefinite-lived intangible assets. Therefore, we performed the impairment assessments of our in-process research and development asset, our long-lived assets, and definite-lived assets and goodwill. In our second step of our goodwill impairment assessment we compared the implied fair value of goodwill to the book value of that goodwill. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the estimated fair value of the business is allocated to all of the assets and liabilities as if the business had been acquired in a business combination and the estimated fair value of the business was the purchase price paid. If the carrying amount goodwill exceeds the implied fair value, an impairment loss is recognized in an amount equal to that excess. We measured the fair value of both our indefinite-lived and definite lived intangible assets using accepted valuation techniques. The significant estimates used included our weighted average cost of capital, long-term rate of growth and profitability of our business, and working capital effects. Our assumptions are based on actual historical performance, expected results after commercial launch of our otlertuzumab product, and implied risk premiums based on market prices of our equity and debt as of the assessment date. To validate the reasonableness of the fair values, we reconciled the aggregate fair values of the business determined in step one to the enterprise market capitalization. Enterprise market capitalization includes, among other factors, the market capitalization of our stock and an acquisition premium based on historical data from acquisitions within the same or similar industries. In performing the reconciliation, we used the market value of our stock price, the stock price on the valuation date and considered such other quantitative and qualitative factors we considered relevant. This assessment resulted in the recognition in the third quarter of 2016 of a loss on impairment of in process research and development costs related to our otlertuzumab candidate of approximately $41.8 million and $29.2 million of goodwill. As evidenced by a significant decline in our stock price, we determined that the adverse change in the business climate discussed above was an indicator requiring the testing of our long-lived assets for recoverability and performed this test as of September 30, 2016, prior to completing the tests above. The results of the evaluation indicated that the carrying values of the related assets were recoverable.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Intangible Assets, Net

12 Months Ended

Dec. 31, 2016

Intangible Assets Net Excluding Goodwill [Abstract]

Intangible Assets, Net

Note 9. Intangible Assets, Net

Intangible assets, net, are comprised of licenses for our suite of commercial products. For the years ended December 31, 2016 and 2015, the Company recorded $2.2 million and $3.4 million, respectively, of intangible asset amortization expense. As of December 31, 2016, the weighted average amortization period remaining for intangible assets was 85 months.

Future amortization expense as of December 31, 2016 is as follows:

(in thousands)
2017	$	2,083
2018		2,083
2019		2,083
2020		2,083
2021 and beyond		6,202
Total remaining amortization	$	14,534

Debt

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Debt

Note 10. Debt

Credit Facility

On August 4, 2016, we entered into a $35.0 million Credit and Security Agreement (the Credit Agreement), with MidCap Financial Trust. The Credit Agreement provides us with up to $35.0 million of available borrowing capacity, available (subject to certain conditions) in two tranches of $20.0 million and $15.0 million, respectively, through August 31, 2017. The loan repayment will include interest (no principal) through August 2018. Commencing in August 2018, the payments will include principal and interest and will be repaid in full on February 1, 2021 (54 months). Amounts drawn under the Credit Agreement bear interest at a rate of LIBOR plus 7.60% per annum. The first tranche of $20.0 million was funded on the closing date of the Credit Agreement with the second tranche of $15.0 million will be available (subject to certain conditions) following the date Aptevo and its subsidiaries: (1) achieve net commercial product revenue of $40.0 million on a trailing twelve-month basis, and (2) receive an additional $20.0 million in cash from Emergent. Emergent’s promise to pay this $20.0 million in cash is evidenced by a non-negotiable, unsecured promissory note issued to Aptevo from Emergent which was paid in the first quarter of 2017. We paid debt issuance costs of $1.9 million.

Five year payments on debt as of December 31, 2016 is as follows:

(in thousands)
2017	$	1,620
2018		4,908
2019		9,053
2020		8,405
2021		671
Total principal and interest payments	$	24,657

The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, in each case applicable to us and our subsidiaries. The negative covenants include restrictions on, among other things, indebtedness, liens, dividends and other distributions, repayment of subordinated indebtedness, mergers, dispositions, investments (including licensing), acquisitions, transactions with affiliates and modification of organizational documents or certain other agreements. The Credit Agreement contains financial covenants that require us and our subsidiaries to maintain increasing minimum net commercial product revenue for each twelve-month period ending on the last day of each calendar quarter, commencing with the twelve-month period ending September 30, 2016. The Credit Agreement also includes provision related to events of default and occurrence of material adverse effect. The occurrence of an event of default could result in the acceleration of the Credit Agreement. There was no event of default under the Credit Agreement as of December 31, 2016.

The Credit Agreement also includes customary events of default, including, among other things, failure to pay principal or interest due under the Credit Agreement, default of covenants, a cross-default on our or our subsidiary’s material indebtedness, breach of material contracts by us or our subsidiaries, or commencement of liquidation, reorganization or similar relief. This and further obligations under the Credit Agreement are secured by all of our assets other than: (1) certain voting shares of excluded subsidiaries, (2) any lease, license or other contract where the grant of a security interest would constitute a default, be prohibited by applicable law, or will require certain third-party consents, and (3) intellectual property (except to the extent necessary to have a lien on such intellectual property in order to have a lien on cash and other proceeds arising out of or derived from such intellectual property).

The related financing documents contain: (1) a customary agency fee, (2) an exit fee of up to 5.75% of the aggregate principal amount under the Credit Agreement for repayment or prepayment other than scheduled amortization payments and the final payment of principal and (3) a prepayment fee of up to 4% of the amount prepaid for the first year, decreasing over time, for any amounts prepaid prior to the maturity date, whether voluntary or by reason of the occurrence of an event of default or acceleration of the loan, other than certain mandatory prepayments.

The obligations of Aptevo and the other borrowers under the Credit Agreement are secured by all of their assets other than (1) certain voting shares of excluded subsidiaries of Aptevo, (2) any lease, license or other contract where the grant of a security interest would constitute a default, be prohibited by applicable law, or will require certain third-party consents and (3) intellectual property of Aptevo (except to the extent necessary to have a lien on such intellectual property in order to have a lien on cash and other proceeds arising out of or derived from such intellectual property).

Net Loss Per Share

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Net Loss Per Share

Note 11. Net Loss per Share

Net loss per share is calculated by dividing the net loss of the Company by the number of weighted shares outstanding on December 31, 2016, and the number of shares issued during the spin-off for prior periods. Prior to the spin-off, Aptevo did not operate as a separate entity and as a result did not have any common stock outstanding other than 1,000 shares held by Emergent. The calculation of basic and diluted net loss per share assumes that the 20,229,849 ordinary shares issued to Aptevo stockholders in connection with the spin-off were outstanding from the beginning of the periods presented. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding during the period. Common stock equivalents are excluded for the twelve-month periods ended December 31, 2016 and 2015, since the effect is anti-dilutive due to the Company’s net losses. Common stock equivalents include stock options and unvested RSUs.

The following table represents all potentially dilutive shares, which were all anti-dilutive and therefore excluded from the calculation of diluted net loss per share:

	As of December 31,
(in thousands, except for per share amounts)	2016
Outstanding options to purchase common stock		2,069
Unvested RSUs		3,034

At December 31, 2015, no options or RSU’s were outstanding.

Equity

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Equity

Note 12. Equity

Capitalization Upon Spin-off

On August 1, 2016, in connection with the spin-off of the Company from Emergent, we issued 20.2 million shares to Emergent shareholders and recorded a contribution from Emergent of $71.2 million. This contribution included a one-time payment of $45.0 million, and a working capital reimbursement for outstanding payments of $1.4 million, which we received in the fourth quarter of 2016, a noncash transfer of an intangible asset of $0.7 million, and a net transfer of cash from Emergent of $24.2 million. In addition, we recorded a promissory note to receive $20.0 million from Emergent, which we received in the first quarter of 2017.

Converted Equity Awards Incentive Plan

The Company had no stock-based compensation plans prior to spin off from Emergent; however certain Aptevo employees participated in Emergent’s stock-based compensation plans (Emergent Plans), which provided for the grants of stock options and restricted stock units (RSUs). The expense associated with Aptevo employees who participated in the Emergent Plans was allocated to the Company in the accompanying Statements of Operations for the associated periods prior to the spin off.

In connection with the spin off and the employee matters agreement, the Company adopted the Converted Equity Awards Incentive Plan (the Converted Plan) and outstanding equity awards of Emergent held by Aptevo employees (the Converted Awards) were converted into or replaced with equity awards of Aptevo (the Conversion Awards) under the Converted Plan and were adjusted to maintain the economic value before and after the distribution date using the relative fair market value of the Emergent and Aptevo common stock based on the closing prices as of August 1, 2016. There was no significant incremental stock-based compensation expense recorded as a result of the equity award conversion. A total of 1.3 million shares of Aptevo common stock have been authorized for issuance under the Converted Plan.

2016 Stock Incentive Plan

On August 1, 2016, the Company adopted the 2016 Stock Incentive Plan (2016 SIP). A total of 3.1 million shares of Aptevo common stock have been authorized for issuance under the 2016 SIP in the form of incentive stock options.

Stock options under the 2016 SIP generally vest pro rata over a three-year period and terminate 7 to 10 years from the grant date, though the specific terms of each grant are determined individually. The Company’s executive officers and certain other employees may be awarded options with different vesting criteria, and options granted to non-employee directors also vest over a three-year period. Option exercise prices for new options granted by the Company equal the closing price of the Company’s common stock on the NASDAQ Global Market on the date of grant, while options issued as Conversion Awards were priced according to the Converted Plan.

RSUs issued under the 2016 SIP or as part of the Converted Plan provide for the issuance of a share of the Company’s common stock at no cost to the holder. RSUs granted to employees under the 2016 SIP generally provide for time-based vesting over an eighteen-month to three-year period, although certain employees may be awarded RSUs with different time-based vesting criteria. Prior to vesting, RSUs granted under the Stock Plan do not have dividend equivalent rights, do not have voting rights and the shares underlying the RSUs are not considered issued or outstanding.

The equity compensation awards granted by the Company generally vest only if the employee is employed by the Company (or in the case of directors, the director continues to serve on the Board) on the vesting date.

Issuance of Shares

When options are exercised or RSU’s are converted, it is the Company’s policy to issue new shares.

Stock-Based Compensation Expense

Stock-based compensation expense includes amortization of stock options and restricted stock units granted to employees and non-employees and has been reported in our Consolidated Statements of Operation and Comprehensive Loss as follows:

(in thousands)	December 31, 2016		December 31, 2015
Research and development	$	2,693	$	1,107
General and administrative		1,116		—
Total stock-based compensation expense	$	3,809	$	1,107

The Company accounts for stock-based compensation by measuring the cost of employee services received in exchange for all equity awards granted based on the fair value of the award as of the grant date. The Company recognizes the compensation expense over the vesting period.

Stock Options

Aptevo utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted:

	December 31, 2016
Expected dividend yield		0.00%
Expected volatility		75.00%
Risk-free interest rate		1.23%
Expected average life of options	6 years

Management applied an estimated forfeiture rate for the 2016 plan period of 10%.

The following is a summary of option activity for the year ended December 31, 2016:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Term		Aggregate Intrinsic Value
Outstanding Aptevo Options at December 31, 2015		—		$	—			$	—
Aggregate impact of conversion related to spin-off		1,672,177			2.49				127,520
Granted		456,075			2.83				35,306
Exercised		(9,144	)		2.15				(8,839	)
Forfeited		(33,894	)		2.48				(5,369	)
Outstanding at December 31, 2016		2,085,214		$	2.57		6.20	$	153,987
Exercisable at December 31, 2016		514,045		$	2.25		4.30	$	119,169

As of December 31, 2016, we had $1.1 million of unrecognized compensation expense related to options expected to vest over a weighted average period of 2.0 years. The weighted average remaining contractual life of outstanding and exercisable options is 6.1 years.

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between the closing stock price of Aptevo’s common stock on the last trading day of 2016 and the exercise price, multiplied by the number of in the money options) that would have been received by the option holders had all the option holders exercised their options on December 31, 2016. The amount of aggregate intrinsic value will change based on the price of Aptevo’s common stock.

Restricted Stock Units

The following is a summary of restricted stock activity for the year ended December 31, 2016:

	Number of Units			Weighted Average Fair Value per Unit		Aggregate Fair Value
Outstanding Aptevo RSU's at December 31, 2015		—		$	—	$	—
Aggregate impact of conversion related to spin-off		1,223,215			2.76		—
Granted		2,115,772			2.94		—
Converted		(140,882	)		2.42		—
Forfeited		(163,910	)		2.90		—
Outstanding at December 31, 2016		3,034,195		$	2.88	$	7,403,435
Expected to Vest		2,801,201		$	2.88	$	6,834,930

As of December 31, 2016, we had $4.6 million of unrecognized compensation expense related to RSU’s expected to vest over a period of 1.3 years. The weighted average remaining contractual life of unvested RSU’s is 3.2 years.

The fair value of each RSU has been determined to be the closing trading price of the Company’s common shares on the date of grant as quoted in NASDAQ Global Market.

401(K) Savings Plan	12 Months Ended
401(K) Savings Plan	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
401(K) Savings Plan	Note 13. 401(k) savings plan Aptevo has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees. Under the 401(k) Plan, employees may make elective salary deferrals. Aptevo currently provides for matching of qualified deferrals up to 50% of 401(k) employee deferral contributions, based on a maximum employee deferral rate of 6% of compensation. During the year ended December 31, 2016 and December 31, 2015, Aptevo’s related share of matching contributions was approximately $0.3 million and $0.3 million.

Leases and Contingencies

12 Months Ended

Dec. 31, 2016

Leases [Abstract]

Leases and Contingencies

Note 14. Leases and Contingencies

The Company leases laboratory and office facilities, and office equipment under operating lease agreements. The Company recognizes rent expense under such arrangements on a straight-line basis over the term of the lease. During the year ended December 31, 2016 and December 31, 2015 total lease expense was $1.8 million and $1.8 million, respectively.

We are committed to future minimum lease payments under operating lease agreements as follows:

Year ending December 31, 2016 (in thousands)
2017	$	1,664
2018		1,620
2019		1,644
Thereafter		554
Total	$	5,482

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 15. Income Taxes

During the periods prior to spin-off, the Company did not file separate tax returns as it was included in the tax returns of Emergent entities within the respective tax jurisdictions. The income tax provision included in these financial statements was calculated using a separate return basis, as if the Company was a separate taxpayer. Under this approach, the Company determines its current taxes, deferred tax assets and liabilities and related tax expense as if it were filing separate tax returns in each tax jurisdiction.

Significant components of the provisions for income taxes attributable to operations consist of the following:

	Year ended December 31,
(in thousands)	2016			2015
Current
International	$	(29	)	$	(660	)
Total current		(29	)		(660	)
Deferred
Federal		(14,630	)		—
State		(681	)		—
International		—			(1,360	)
Total deferred		(15,311	)		(1,360	)
Total benefit from income taxes	$	(15,340	)	$	(2,020	)

The Company’s net deferred tax asset (liability) consists of the following:

	December 31,
(in thousands)	2016			2015 (Restated)
Federal losses carryforward	$	7,237		$	90,121
Other tax credits		384			13,026
Scientific research and experimental development credit carryforward		—			3,460
State losses carryforward		371			—
Intangible assets		17,464			—
Stock compensation		1,726			1,167
Foreign deferrals		—			17,755
Inventory reserves		—			1,716
Fixed assets		160			1,357
Other		3,050			3,910
Deferred tax asset		30,392			132,512
Intangibles		—			(13,043	)
Other		(575	)		(797	)
Deferred tax liability		(575	)		(13,840	)
Valuation allowance		(29,817	)		(134,489	)
Net deferred tax liabilities	$	—		$	(15,817	)

For the year ended December 31, 2015, deferred assets and liabilities are a result of the separate return calculation presentation and may not represent deferred assets and liability balances after the distribution. Certain deferred items may not have existed due to utilization by the Emergent group prior to the distribution, together with certain related transactions, or may hold no future value subsequent to the distribution due to the Company’s future jurisdictional income projections. Federal net operating losses and research and development credit carryforwards are examples of deferred items that have been previously utilized or will have no future value to the Company as the distribution, together with certain related transactions, did not result in the transfer of loss carryforwards or tax credit carryforwards to the Company. The Company has determined a valuation allowance is required for financial reporting purposes due to cumulative historic losses on a separate tax return basis as well as the expiration of certain attributes.

As of December 31, 2016 and 2015, the Company has recorded federal net operating losses of approximately $20.7 and $257.4 million, respectively, state tax losses of $10.5 million and $0.0, respectively, and tax credits of $0.4 million and $13.2 million, respectively. In addition, the Company has recorded Canadian loss carryforwards of approximately $0.0 and $68.3 million, respectively, and Canadian scientific research and experimental development credits in the amount of $0.0 and $3.5 million, respectively. On a separate return basis, the US losses and credits would begin to expire in 2037. The state net operating losses will begin to expire in varying periods. The Emergent group retained the Canadian losses, Canadian tax credits and pre-spin federal losses and research and development tax credits. Carryforwards of net operating losses are subject to possible limitation, should a change in ownership occur, as defined by Internal Revenue Code Section 382.

The valuation allowance as of December 31, 2016 is primarily related to net operating losses and intangibles. The net change in valuation allowance was a decrease of $83.3 million.

The Company files income tax returns in the US and several state jurisdictions. The 2016 tax filings are open to review by taxing authorities.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits:

	December 31,
(in thousands)	2016		2015
Balance at the beginning of the year	$	—	$	—
Increases (decreases) related to prior period tax positions		76		—
Increases (decreases) related to current period tax positions		—		—
Balance at the end of the year	$	76	$	—

We recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, no interest and penalties have been recognized related to the underpayment of income taxes.

The benefit from income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before benefit from income taxes as a result of the following

	Year ended December 31,
(in thousands)	2016			2015
US	$	(123,199	)	$	(41,648	)
International		(4,556	)		(19,689	)
Loss before benefit from income taxes	$	(127,755	)	$	(61,337	)
Federal tax at statutory rates	$	(44,714	)	$	(21,467	)
State taxes, net of federal benefit		(1,189	)		419
Impact of foreign operations		(29	)		1,828
Change in valuation allowance		9,549			20,563
Separation related adjustment		11,055			—
Tax credits		(460	)		(3,898	)
Unrecognized tax benefits of tax credits		76			—
Permanent differences		10,372			535
Benefit from income taxes	$	(15,340	)	$	(2,020	)

Selected Quarterly Financial Data (unaudited)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data (unaudited)

Note 17. Selected Quarterly Financial Data (unaudited)

Impact of Restatement

As detailed in Note 2, the Company has restated its consolidated balance sheet as of December 31, 2015. Accordingly, the Company has restated its consolidated balance sheet as of March 31, 2016 and June 30, 2016. In addition, the Company has restated its statements of operations for the quarterly and nine month periods ended September 30, 2016. The restatement resulted in the recognition of a $15.3 million benefit from income taxes equal to the amount of the deferred tax liability recorded associated with the TRU-016 IPR&D asset when the $41.8 million was impaired. The restatement also resulted in an increase in the impairment expense recognized in the third quarter of 2016 due to the impairment of all goodwill, by the amount that goodwill would have been increased. These two restated captions on the statements of operations have the effect of offsetting each other, resulting in no impact to net loss for the quarter and nine months ended September 30, 2016. The restatement adjustment did not impact the consolidated statement of operations for any periods prior to the third quarter of 2016.

The impact of the restatement on the Company’s consolidated balance sheets and statements of operations is reflected and quantified for all interim periods affected, as applicable, in the below tables.

Balance Sheets Impact:

(in thousands)	March 31, 2016 (As previously reported)		Restatement Adjustment		March 31, 2016 (Restated)		June 30, 2016 (As previously reported)		Restatement Adjustment		June 30, 2016 (Restated)
Goodwill	$	13,902	$	15,311	$	29,213	$	13,902	$	15,311	$	29,213
Total assets		112,605		15,311		127,916		118,159		15,311		133,470

Deferred tax liability		506		15,311		15,817		506		15,311		15,817
Total liabilities	$	22,743	$	15,311	$	38,054	$	20,962	$	15,311	$	36,273
Total stockholders equity	$	89,862	$	—	$	89,862	$	97,197	$	—	$	97,197

Statement of Operations Impact:

	Three Months Ended									Nine Months Ended
(in thousands)	September 30, 2016 (As previously reported)			Restatement Adjustment			September 30, 2016 (Restated)			September 30, 2016 (As previously reported)			Restatement Adjustment			September 30, 2016 (Restated)
Impairment expense	$	55,702		$	15,311		$	71,013		$	55,702		$	15,311		$	71,013
Loss from operations		(71,254	)		(15,311	)		(86,565	)		(97,081	)		(15,311	)		(112,392	)
Loss before income taxes		(71,747	)		(15,311	)		(87,058	)		(97,498	)		(15,311	)		(112,809	)
Benefit from income taxes		6			15,311			15,317			29			15,311			15,340
Net loss	$	(71,741	)	$	—		$	(71,741	)	$	(97,469	)	$	—		$	(97,469	)

The following table sets forth our unaudited quarterly consolidated statement of operations data for the eight quarters ended December 31, 2016:

2016
(in thousands, except per share amounts)	March 31,			June 30,			September 30, (Restated) ⁽¹⁾			December 31,
Revenue	$	8,067		$	10,193		$	9,405		$	8,769
Loss from operations		(12,982	)		(12,845	)		(86,565	)		(14,553	)
Loss before income taxes		(12,902	)		(12,849	)		(87,058	)		(14,946	)
Benefit from income taxes		12			11			15,317			—
Net loss	$	(12,890	)	$	(12,838	)	$	(71,741	)	$	(14,946	)
Net loss per share - basic and diluted	$	(0.64	)	$	(0.63	)	$	(3.55	)	$	(0.74	)

2015
(in thousands, except per share amounts)	March 31,			June 30,			September 30,			December 31,
Revenue	$	11,663		$	7,090		$	6,562		$	8,286
Loss from operations		(11,102	)		(18,310	)		(13,188	)		(18,500	)
Loss before income taxes		(11,397	)		(18,328	)		(13,104	)		(18,508	)
Benefit from income taxes		375			612			424			610
Net loss	$	(11,022	)	$	(17,716	)	$	(12,680	)	$	(17,898	)
Net loss per share - basic and diluted	$	(0.54	)	$	(0.88	)	$	(0.63	)	$	(0.88	)

⁽¹⁾ These amounts reflect a benefit from income taxes after giving effect to the goodwill and deferred tax liability restatement discussed above. The impairment of the Company’s IPR&D in the quarter ended September 30, 2016 resulted in a benefit from income taxes of $15.3 million related to the reversal of the associated deferred tax liability in that quarter. The Company’s interim financial statements included in Form 10-Q for the quarter ended September 30, 2016 did not reflect this benefit from income taxes or the increase in impairment of goodwill.

Nature of Business and Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Cash Equivalents

Short-Term Investments

Concentrations of Credit Risk

Accounts Receivable

Inventories

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Furniture and equipment	7-10 years
Software and hardware	3-5 years or product life
Leasehold improvements	Lesser of the asset life or the remaining lease term

In-Process Research and Development and Long-lived Assets

Goodwill

Contingent Consideration

Fair Value of Financial Instruments

Sales Rebates and other Discounts

Research and Development

Selling, General and Administrative Expenses

Stock-Based Compensation

•

the risk-free interest rate, which we based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued;

•

the expected dividend yield, which we estimate to be zero based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends; and

•

the fair value of our common stock on the date of grant.

Income Taxes

Segment Reporting

The Company has determined that it operates in a single segment and has one reporting unit: the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.

New Accounting Pronouncements

Restatement (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Changes And Error Corrections [Abstract]

Impact of Restatement on Consolidated Balance Sheets and Statements of Operations for Periods Affected

The impact of the restatement on the Company’s consolidated balance sheets is reflected and quantified for 2015 in the below table.

Balance Sheet Impact:

⁽¹⁾


(in thousands)	December 31, 2015 (As previously reported)		Restatement Adjustment		December 31, 2015 (Restated)
Goodwill	$	13,902	$	15,311	$	29,213
Total assets		112,456		15,311		127,767

Deferred tax liability		506		15,311		15,817
Total liabilities	$	23,838	$	15,311	$	39,149
Total stockholders equity	$	88,618	$	—	$	88,618

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Summary of Financial Assets Measured at Fair Value

The Company’s financial assets measured at fair value consisted of the following as of December 31, 2016

	December 31, 2016
(in thousands)	Level 1		Level 2		Level 3		Total
Financial Assets:
Money market funds	$	5,215	$	—	$	—	$	5,215
Corporate bonds		—		9,951		—		9,951
US government and agency debt securities		—		34,898		—		34,898
Total assets	$	5,215	$	44,849	$	—	$	50,064

Summary of Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

(in thousands)
Balance at December 31, 2015	$	444
Expense included in earnings		19
Settlements		(463	)
Balance at December 31, 2016	$	—

Investments (Tables)

12 Months Ended

Dec. 31, 2016

Investments Debt And Equity Securities [Abstract]

Schedule of short-term investments

All short-term investments are limited to a final maturity of less than one year from the reporting date

	December 31, 2016
(in thousands)	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding (Losses)			Estimated Fair Value
Cash equivalents:
Money market fund	$	5,215	$	—	$	—		$	5,215
Total cash equivalents	$	5,215	$	—	$	—		$	5,215

Short-term investments:
Corporate bonds	$	9,959	$	1	$	(9	)	$	9,951
US government and agency debt securities		34,923		—		(25	)		34,898
Total short-term investments	$	44,882	$	1	$	(34	)	$	44,849

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventories (Tables)

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:

	December 31,		December 31,
(in thousands)	2016		2015
Raw materials and supplies	$	260	$	6,520
Work-in-process		1,165		4,730
Finished goods		5,214		9,072
Total inventories	$	6,639	$	20,322

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Summary of Property, Plant and Equipment

Property, plant and equipment consist of the following:

	December 31,			December 31,
(in thousands)	2016			2015
Leasehold improvements	$	2,265		$	2,152
Furniture and equipment		10,283			7,884
Property and equipment, gross		12,548			10,036
Less: Accumulated depreciation		(6,638	)		(5,857	)
Total property and equipment, net	$	5,910		$	4,179

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2016

Intangible Assets Net Excluding Goodwill [Abstract]

Summary of Intangible Assets

Schedule of Future Amortization Expense

Future amortization expense as of December 31, 2016 is as follows:

(in thousands)
2017	$	2,083
2018		2,083
2019		2,083
2020		2,083
2021 and beyond		6,202
Total remaining amortization	$	14,534

Debt (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Schedule of Five Year Payments on Debt

Five year payments on debt as of December 31, 2016 is as follows:

(in thousands)
2017	$	1,620
2018		4,908
2019		9,053
2020		8,405
2021		671
Total principal and interest payments	$	24,657

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Summary of Potentially Dilutive Shares Excluded from Calculation of Net Loss Per Share

The following table represents all potentially dilutive shares, which were all anti-dilutive and therefore excluded from the calculation of diluted net loss per share:

	As of December 31,
(in thousands, except for per share amounts)	2016
Outstanding options to purchase common stock		2,069
Unvested RSUs		3,034

Equity (Tables)

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Summary of Stock-based Compensation Expense Includes Amortization of Stock Options and Restricted Stock Units Granted

(in thousands)	December 31, 2016		December 31, 2015
Research and development	$	2,693	$	1,107
General and administrative		1,116		—
Total stock-based compensation expense	$	3,809	$	1,107

Assumptions used in Valuing the Stock Options Granted under Black-Scholes Valuation Model

Aptevo utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted:

	December 31, 2016
Expected dividend yield		0.00%
Expected volatility		75.00%
Risk-free interest rate		1.23%
Expected average life of options	6 years

Summary of Stock Option Activity

The following is a summary of option activity for the year ended December 31, 2016:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Term		Aggregate Intrinsic Value
Outstanding Aptevo Options at December 31, 2015		—		$	—			$	—
Aggregate impact of conversion related to spin-off		1,672,177			2.49				127,520
Granted		456,075			2.83				35,306
Exercised		(9,144	)		2.15				(8,839	)
Forfeited		(33,894	)		2.48				(5,369	)
Outstanding at December 31, 2016		2,085,214		$	2.57		6.20	$	153,987
Exercisable at December 31, 2016		514,045		$	2.25		4.30	$	119,169

Summary of Restricted Stock Activity

The following is a summary of restricted stock activity for the year ended December 31, 2016:

	Number of Units			Weighted Average Fair Value per Unit		Aggregate Fair Value
Outstanding Aptevo RSU's at December 31, 2015		—		$	—	$	—
Aggregate impact of conversion related to spin-off		1,223,215			2.76		—
Granted		2,115,772			2.94		—
Converted		(140,882	)		2.42		—
Forfeited		(163,910	)		2.90		—
Outstanding at December 31, 2016		3,034,195		$	2.88	$	7,403,435
Expected to Vest		2,801,201		$	2.88	$	6,834,930

Leases and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Leases [Abstract]

Summary of Future Minimum Lease Payments Under Operating Lease Agreements

We are committed to future minimum lease payments under operating lease agreements as follows:

Year ending December 31, 2016 (in thousands)
2017	$	1,664
2018		1,620
2019		1,644
Thereafter		554
Total	$	5,482

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Summary of Significant Components of Provisions for Income Taxes Attributable to Operations

Significant components of the provisions for income taxes attributable to operations consist of the following:

	Year ended December 31,
(in thousands)	2016			2015
Current
International	$	(29	)	$	(660	)
Total current		(29	)		(660	)
Deferred
Federal		(14,630	)		—
State		(681	)		—
International		—			(1,360	)
Total deferred		(15,311	)		(1,360	)
Total benefit from income taxes	$	(15,340	)	$	(2,020	)

Schedule of Net Deferred Tax Asset (Liability)

The Company’s net deferred tax asset (liability) consists of the following:

	December 31,
(in thousands)	2016			2015 (Restated)
Federal losses carryforward	$	7,237		$	90,121
Other tax credits		384			13,026
Scientific research and experimental development credit carryforward		—			3,460
State losses carryforward		371			—
Intangible assets		17,464			—
Stock compensation		1,726			1,167
Foreign deferrals		—			17,755
Inventory reserves		—			1,716
Fixed assets		160			1,357
Other		3,050			3,910
Deferred tax asset		30,392			132,512
Intangibles		—			(13,043	)
Other		(575	)		(797	)
Deferred tax liability		(575	)		(13,840	)
Valuation allowance		(29,817	)		(134,489	)
Net deferred tax liabilities	$	—		$	(15,817	)

Schedule of Reconciliation of Unrecognized Tax Benefits

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits:

	December 31,
(in thousands)	2016		2015
Balance at the beginning of the year	$	—	$	—
Increases (decreases) related to prior period tax positions		76		—
Increases (decreases) related to current period tax positions		—		—
Balance at the end of the year	$	76	$	—

Schedule of Benefit from Income Taxes Differs from Amount of Taxes Determined by Applying U.S. Federal Statuary Rate to Loss before Benefit from Income Taxes

The benefit from income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before benefit from income taxes as a result of the following

	Year ended December 31,
(in thousands)	2016			2015
US	$	(123,199	)	$	(41,648	)
International		(4,556	)		(19,689	)
Loss before benefit from income taxes	$	(127,755	)	$	(61,337	)
Federal tax at statutory rates	$	(44,714	)	$	(21,467	)
State taxes, net of federal benefit		(1,189	)		419
Impact of foreign operations		(29	)		1,828
Change in valuation allowance		9,549			20,563
Separation related adjustment		11,055			—
Tax credits		(460	)		(3,898	)
Unrecognized tax benefits of tax credits		76			—
Permanent differences		10,372			535
Benefit from income taxes	$	(15,340	)	$	(2,020	)

Selected Quarterly Financial Data (unaudited) (Tables)

12 Months Ended

Dec. 31, 2016

Impact of Restatement on Consolidated Balance Sheets and Statements of Operations for Periods Affected

The impact of the restatement on the Company’s consolidated balance sheets is reflected and quantified for 2015 in the below table.

Balance Sheet Impact:

⁽¹⁾


(in thousands)	December 31, 2015 (As previously reported)		Restatement Adjustment		December 31, 2015 (Restated)
Goodwill	$	13,902	$	15,311	$	29,213
Total assets		112,456		15,311		127,767

Deferred tax liability		506		15,311		15,817
Total liabilities	$	23,838	$	15,311	$	39,149
Total stockholders equity	$	88,618	$	—	$	88,618

Selected Quarterly Financial Data

The following table sets forth our unaudited quarterly consolidated statement of operations data for the eight quarters ended December 31, 2016:

2016
(in thousands, except per share amounts)	March 31,			June 30,			September 30, (Restated) ⁽¹⁾			December 31,
Revenue	$	8,067		$	10,193		$	9,405		$	8,769
Loss from operations		(12,982	)		(12,845	)		(86,565	)		(14,553	)
Loss before income taxes		(12,902	)		(12,849	)		(87,058	)		(14,946	)
Benefit from income taxes		12			11			15,317			—
Net loss	$	(12,890	)	$	(12,838	)	$	(71,741	)	$	(14,946	)
Net loss per share - basic and diluted	$	(0.64	)	$	(0.63	)	$	(3.55	)	$	(0.74	)

2015
(in thousands, except per share amounts)	March 31,			June 30,			September 30,			December 31,
Revenue	$	11,663		$	7,090		$	6,562		$	8,286
Loss from operations		(11,102	)		(18,310	)		(13,188	)		(18,500	)
Loss before income taxes		(11,397	)		(18,328	)		(13,104	)		(18,508	)
Benefit from income taxes		375			612			424			610
Net loss	$	(11,022	)	$	(17,716	)	$	(12,680	)	$	(17,898	)
Net loss per share - basic and diluted	$	(0.54	)	$	(0.88	)	$	(0.63	)	$	(0.88	)

Balance Sheets Restatement

Impact of Restatement on Consolidated Balance Sheets and Statements of Operations for Periods Affected

Balance Sheets Impact:

(in thousands)	March 31, 2016 (As previously reported)		Restatement Adjustment		March 31, 2016 (Restated)		June 30, 2016 (As previously reported)		Restatement Adjustment		June 30, 2016 (Restated)
Goodwill	$	13,902	$	15,311	$	29,213	$	13,902	$	15,311	$	29,213
Total assets		112,605		15,311		127,916		118,159		15,311		133,470

Deferred tax liability		506		15,311		15,817		506		15,311		15,817
Total liabilities	$	22,743	$	15,311	$	38,054	$	20,962	$	15,311	$	36,273
Total stockholders equity	$	89,862	$	—	$	89,862	$	97,197	$	—	$	97,197

Statement of Operations Restatement

Impact of Restatement on Consolidated Balance Sheets and Statements of Operations for Periods Affected

Statement of Operations Impact:

	Three Months Ended									Nine Months Ended
(in thousands)	September 30, 2016 (As previously reported)			Restatement Adjustment			September 30, 2016 (Restated)			September 30, 2016 (As previously reported)			Restatement Adjustment			September 30, 2016 (Restated)
Impairment expense	$	55,702		$	15,311		$	71,013		$	55,702		$	15,311		$	71,013
Loss from operations		(71,254	)		(15,311	)		(86,565	)		(97,081	)		(15,311	)		(112,392	)
Loss before income taxes		(71,747	)		(15,311	)		(87,058	)		(97,498	)		(15,311	)		(112,809	)
Benefit from income taxes		6			15,311			15,317			29			15,311			15,340
Net loss	$	(71,741	)	$	—		$	(71,741	)	$	(97,469	)	$	—		$	(97,469	)

Nature of Business and Significant Accounting Policies - Additional Information (Details)		3 Months Ended	12 Months Ended
	Aug. 02, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($) Distributor Segment Unit	Dec. 31, 2015 USD ($)	Mar. 31, 2017 USD ($)	Aug. 04, 2016 USD ($)
Nature Of Business [Line Items]
Spin off transaction separation distribution agreement date			Aug. 01, 2016
Transfer from former parent, prior to spin-off			$ 71,219,000	$ 52,220,000
Noncash transfer of intangible asset	$ 700,000
Cash funding committed by Emergent in connection with spin-off		$ 20,000,000	20,000,000
Maximum borrowing capacity						$ 35,000,000
Restricted cash		400,000	400,000
Allowance for doubtful accounts		3,300,000	$ 3,300,000	$ 3,500,000
Number of operating segment \| Segment			1
Number of reporting unit \| Unit			1
Stock Option
Nature Of Business [Line Items]
Expected dividend yield			0.00%
Estimated forfeiture rate			10.00%
RSUs and Options
Nature Of Business [Line Items]
Estimated forfeiture rate			10.00%
Credit Facility First Tranche
Nature Of Business [Line Items]
Maximum borrowing capacity						20,000,000
Credit Facility Second Tranche
Nature Of Business [Line Items]
Maximum borrowing capacity						$ 15,000,000
Emergent
Nature Of Business [Line Items]
Business close of date			Aug. 01, 2016
Emergent \| Canada
Nature Of Business [Line Items]
Number of distributors related to sales agreement \| Distributor			2
Emergent \| Promissory Note \| Scenario Forecast
Nature Of Business [Line Items]
Cash funding committed by Emergent in connection with spin-off					$ 20,000,000
Emergent \| Spin-off
Nature Of Business [Line Items]
Transfer from former parent, prior to spin-off	71,200,000
One-time payment amount	45,000,000
Working capital reimbursement for outstanding payments		$ 1,400,000
Noncash transfer of intangible asset	700,000
Net transfers of cash from former parent	$ 24,200,000
Emergent \| Common Stock
Nature Of Business [Line Items]
Ratio of stock received by Emergent’s shareholders	0.5

Nature of Business and Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2016
Furniture and Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated useful lives	7 years
Furniture and Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated useful lives	10 years
Software and Hardware
Property Plant And Equipment [Line Items]
Estimated useful lives	product life
Software and Hardware \| Minimum
Property Plant And Equipment [Line Items]
Estimated useful lives	3 years
Software and Hardware \| Maximum
Property Plant And Equipment [Line Items]
Estimated useful lives	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Estimated useful lives	Lesser of the asset life or the remaining lease term

Restatement - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Error Corrections And Prior Period Adjustments Restatement [Line Items]
IPR&D assets recorded				$ 41,800
Increase in deferred tax liabilities		$ 15,817	$ 15,817	15,817
Impact on total Equity	$ 50,566	97,197	89,862	88,618	$ 94,608
Goodwill		29,213	29,213	29,213
Restatement Adjustment
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase in deferred tax liabilities		15,311	15,311	15,311
Impact on total Equity		0	0	0
Goodwill		$ 15,311	$ 15,311	15,311
Trubion Pharmaceuticals, Inc.
Error Corrections And Prior Period Adjustments Restatement [Line Items]
IPR&D assets recorded				$ 41,800

Restatement - Balance Sheet Impact (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Goodwill		$ 29,213	$ 29,213	$ 29,213
Total assets	$ 91,858	133,470	127,916	127,767
Deferred income taxes		15,817	15,817	15,817
Total liabilities	41,292	36,273	38,054	39,149
Total stockholders equity	$ 50,566	97,197	89,862	88,618	$ 94,608
As Previously Reported
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Goodwill		13,902	13,902	13,902
Total assets		118,159	112,605	112,456
Deferred income taxes		506	506	506
Total liabilities		20,962	22,743	23,838
Total stockholders equity		97,197	89,862	88,618
Restatement Adjustment
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Goodwill		15,311	15,311	15,311
Total assets		15,311	15,311	15,311
Deferred income taxes		15,311	15,311	15,311
Total liabilities		15,311	15,311	15,311
Total stockholders equity		$ 0	$ 0	$ 0

MorphoSys Collaboration Agreement - Additional Information (Details)	1 Months Ended			6 Months Ended	12 Months Ended
	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Aug. 31, 2014 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2016 USD ($) Unit	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reduction to research and development expense					$ 29,518,000	$ 34,726,000
MorphoSys Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Nonrefundable upfront payment received			$ 20,000,000
Additional contingent payment that may be receive			$ 163,000,000
First contingent payment received based upon development and regulatory milestones				$ 5,000,000
Collaborative agreement, rights and obligations					MorphoSys and Aptevo jointly agreed to fund further development of MOR209/ES414, with Aptevo responsible for 36% of the total development costs and MorphoSys responsible for the remainder.
Maximum percentage of tiered royalty obligation on sales			20.00%
Number of units of accounting \| Unit					2
Allocation of collaborative arrangements upfront payment units of accounting							$ 20,000,000
Upfront payment allocated to license fee unit							15,300,000
Upfront payment allocated to service development							$ 4,700,000
License revenue			$ 15,300,000
Revenue recognized					$ 100,000	500,000
Current estimated service period for undelivered development services					2023
Reduction to research and development expense					$ 100,000	$ 4,300,000
Accounts receivable	$ 0				0
Deferred revenue	$ 3,700,000				$ 3,700,000
Maximum \| MorphoSys Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
First contingent payment received based upon development and regulatory milestones		$ 32,500,000	80,000,000
Second contingent payment received based upon development and regulatory milestones		41,500,000	$ 83,000,000
Aptevo \| MorphoSys Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share of joint development costs percentage			36.00%
Maximum funding requirement cap		$ 250,000,000	$ 186,000,000
Aptevo \| Morpho Sys Agreement January 1, 2017 through June 30, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share of joint development costs percentage	75.00%
Aptevo \| Morpho Sys Agreement July 1, 2017 through December 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share of joint development costs percentage	49.00%
Aptevo \| Morpho Sys Agreement Beyond January 1, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share of joint development costs percentage	36.00%
MorphoSys \| Morpho Sys Agreement January 1, 2017 through June 30, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share of joint development costs percentage	25.00%
MorphoSys \| Morpho Sys Agreement July 1, 2017 through December 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share of joint development costs percentage	51.00%
MorphoSys \| Morpho Sys Agreement Beyond January 1, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share of joint development costs percentage	64.00%

Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Financial assets measured at fair value	$ 50,064,000	$ 0
Fair value assets, level 1 to level 2 transfers	0
Fair value assets, level 2 to level 1 transfers	$ 0
Royalty agreement expiration date	Jun. 30, 2016
Future royalty payments expected	$ 0

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Financial Assets:
Assets fair value	$ 50,064,000	$ 0
Level 1
Financial Assets:
Assets fair value	5,215,000
Level 2
Financial Assets:
Assets fair value	44,849,000
Money Market Funds
Financial Assets:
Assets fair value	5,215,000
Money Market Funds \| Level 1
Financial Assets:
Assets fair value	5,215,000
Corporate Bonds
Financial Assets:
Assets fair value	9,951,000
Corporate Bonds \| Level 2
Financial Assets:
Assets fair value	9,951,000
US Government and Agency Debt Securities
Financial Assets:
Assets fair value	34,898,000
US Government and Agency Debt Securities \| Level 2
Financial Assets:
Assets fair value	$ 34,898,000

Fair Value Measurements - Summary of Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Fair Value Disclosures [Abstract]
Beginning balance	$ 444
Expense included in earnings	19
Settlements	$ (463)

Investments - Schedule of Short-term Investments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Short-term Investments
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 44,882
Gross Unrealized Holding Gains	1
Gross Unrealized Holding (Losses)	(34)
Estimated Fair Value	44,849
Short-term Investments \| Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	9,959
Gross Unrealized Holding Gains	1
Gross Unrealized Holding (Losses)	(9)
Estimated Fair Value	9,951
Short-term Investments \| US Government and Agency Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	34,923
Gross Unrealized Holding (Losses)	(25)
Estimated Fair Value	34,898
Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	5,215
Estimated Fair Value	5,215
Cash Equivalents \| Money Market Fund
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	5,215
Estimated Fair Value	$ 5,215

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Adjustments [Abstract]
Raw materials and supplies	$ 260	$ 6,520
Work-in-process	1,165	4,730
Finished goods	5,214	9,072
Total inventories	$ 6,639	$ 20,322

Property and Equipment, Net - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 12,548	$ 10,036
Less: Accumulated depreciation	(6,638)	(5,857)
Total property and equipment, net	5,910	4,179
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,265	2,152
Furniture and Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 10,283	$ 7,884

Impairment of Intangible Assets, In-Process Research and Development and Goodwill - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Loss on impairment of in process research and development costs	$ 41.8	$ 41.8
Goodwill impairment loss	$ 29.2

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Intangible Assets Net Excluding Goodwill [Abstract]
Amortization expense	$ 2.2	$ 3.4
Weighted average remaining amortization period	85 months

Intangible Assets, Net - Schedule of Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2017	$ 2,083
2018	2,083
2019	2,083
2020	2,083
2021 and beyond	6,202
Net book value at December 31, 2016	$ 14,534

Debt - Additional Information (Details) - USD ($)		12 Months Ended
Debt - Additional Information (Details) - USD ($)	Aug. 04, 2016	Dec. 31, 2016
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 35,000,000
Credit facility repayment term, description		The loan repayment will include interest (no principal) through August 2018. Commencing in August 2018, the payments will include principal and interest and will be repaid in full on February 1, 2021 (54 months).
Credit facility repayment period	54 months
Maturity date of credit agreement	Feb. 01, 2021
Credit agreement reference rate for the variable rate		LIBOR
Credit agreement basis spread on variable rate	7.60%
Cash funding committed by Emergent in connection with spin-off		$ 20,000,000
Debt issuance costs	$ 1,900,000	$ 1,962,000
Credit agreement exit fee, percentage	5.75%
Credit agreement prepayment fee for first year, percentage	4.00%
Credit Facility First Tranche
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 20,000,000
Credit Facility Second Tranche
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	15,000,000
Net commercial product revenue required to be achieved on trailing twelve month basis	40,000,000
Emergent \| Non Negotiable Unsecured Promissory Note
Line Of Credit Facility [Line Items]
Cash funding committed by Emergent in connection with spin-off	$ 20,000,000

Debt - Schedule of Five Year Payments on Debt (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Debt Disclosure [Abstract]
2017	$ 1,620
2018	4,908
2019	9,053
2020	8,405
2021	671
Total principal and interest payments	$ 24,657

Net Loss Per Share - Additional Information (Details) - shares	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Ordinary shares outstanding	20,271,737	0
Ordinary shares issued in connection with spin-off	20,271,737	0
Stock Option
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Options outstanding	2,085,214	0
Restricted Stock Units
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
RSU's outstanding	3,034,195	0
Emergent
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Ordinary shares outstanding	1,000
Spin-off
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Ordinary shares issued in connection with spin-off	20,229,849

Net Loss Per Share - Summary of Potentially Dilutive Shares Excluded from Calculation of Net Loss Per Share (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2016 shares
Outstanding Options to Purchase Common Stock
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	2,069
Unvested RSUs
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	3,034

Equity - Additional Information (Details) - USD ($)		3 Months Ended	12 Months Ended
Equity - Additional Information (Details) - USD ($)	Aug. 02, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2017	Aug. 01, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Transfer from former parent, prior to spin-off			$ 71,219,000	$ 52,220,000
Noncash transfer of intangible asset	$ 700,000
Cash funding committed by Emergent in connection with spin-off		$ 20,000,000	20,000,000
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense		4,600,000	$ 4,600,000
Expected vesting period			1 year 3 months 18 days
Weighted average remaining contractual life			3 years 2 months 12 days
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeiture rate			10.00%
Unrecognized compensation expense		1,100,000	$ 1,100,000
Options expected to vest , weighted average period			2 years
Options outstanding and exercisable weighted average remaining contractual life			6 years 1 month 6 days
Converted Equity Awards Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Incremental stock-based compensation expense recorded as result of equity award conversion	$ 0
Converted Equity Awards Incentive Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock authorized for issuance under Stock Plan						1,300,000
2016 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock authorized for issuance under Stock Plan						3,100,000
Stock plan vesting period	3 years
2016 Stock Incentive Plan \| Non-employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock plan vesting period	3 years
2016 Stock Incentive Plan \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock plan termination period	7 years
2016 Stock Incentive Plan \| Minimum \| Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock plan vesting period	18 months
2016 Stock Incentive Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock plan termination period	10 years
2016 Stock Incentive Plan \| Maximum \| Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock plan vesting period	3 years
Promissory Note \| Emergent \| Scenario Forecast
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash funding committed by Emergent in connection with spin-off					$ 20,000,000
Spin-off \| Emergent
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued						20,200,000
Transfer from former parent, prior to spin-off	$ 71,200,000
One-time payment amount	45,000,000
Working capital reimbursement for outstanding payments		$ 1,400,000
Noncash transfer of intangible asset	700,000
Net transfers of cash from former parent	$ 24,200,000

Equity - Summary of Stock-based Compensation Expense Includes Amortization of Stock Options and Restricted Stock Units Granted (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 3,809	$ 1,107
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	2,693	$ 1,107
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,116

Equity - Assumptions used in Valuing the Stock Options Granted under Black-Scholes Valuation Model (Details) - Stock Option	12 Months Ended
	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Expected volatility	75.00%
Risk-free interest rate	1.23%
Expected average life of options	6 years

Equity - Summary of Stock Option Activity (Details) - Stock Option	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning balance	0
Number of Shares, Aggregate impact of conversion related to spin-off	1,672,177
Number of Shares, Granted	456,075
Number of Shares, Exercised	(9,144)
Number of Shares, Forfeited	(33,894)
Number of Shares, Outstanding, Ending balance	2,085,214
Number of Shares, Exercisable	514,045
Weighted-Average Exercise Price, Aggregate impact of conversion related to spin-off \| $ / shares	$ 2.49
Weighted-Average Exercise Price, Granted \| $ / shares	2.83
Weighted-Average Exercise Price, Exercised \| $ / shares	2.15
Weighted-Average Exercise Price, Forfeited \| $ / shares	2.48
Weighted-Average Exercise Price, Outstanding, Ending balance \| $ / shares	2.57
Weighted-Average Exercise Price, Exercisable \| $ / shares	$ 2.25
Weighted-Average Remaining Term, Outstanding	6 years 2 months 12 days
Weighted-Average Remaining Term, Exercisable	4 years 3 months 18 days
Aggregate Intrinsic Value, Aggregate impact of conversion related to spin-off \| $	$ 127,520
Aggregate Intrinsic Value, Granted \| $	35,306
Aggregate Intrinsic Value, Exercised \| $	(8,839)
Aggregate Intrinsic Value, Forfeited \| $	(5,369)
Aggregate Intrinsic Value, Outstanding, Ending balance \| $	153,987
Aggregate Intrinsic Value, Exercisable \| $	$ 119,169

Equity - Summary of Restricted Stock Activity (Details) - Restricted Stock Units	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Outstanding, Beginning balance	0
Number of Units, Aggregate impact of conversion related to spin-off	1,223,215
Number of Units, Granted	2,115,772
Number of Units, Converted	(140,882)
Number of Units, Forfeited	(163,910)
Number of Units, Outstanding, Ending balance	3,034,195
Number of Units, Expected to Vest	2,801,201
Weighted Average Fair Value per Unit, Aggregate impact of conversion related to spin-off \| $ / shares	$ 2.76
Weighted Average Fair Value per Unit, Granted \| $ / shares	2.94
Weighted Average Fair Value per Unit, Converted \| $ / shares	2.42
Weighted Average Fair Value per Unit, Forfeited \| $ / shares	2.90
Weighted Average Fair Value per Unit, Outstanding Ending Balance \| $ / shares	2.88
Weighted Average Fair Value per Unit, Expected to Vest \| $ / shares	$ 2.88
Aggregate Fair Value, Outstanding, Ending balance \| $	$ 7,403,435
Aggregate Fair Value, Expected to Vest \| $	$ 6,834,930

401(K) Savings Plan - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan Disclosure [Line Items]
Maximum employee deferral rate	6.00%
Matching contributions made by employer	$ 0.3	$ 0.3
Maximum
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, qualified deferral percentage	50.00%

Leases and Contingencies - Summary of Future Minimum Lease Payments Under Operating Lease Agreements (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Leases [Abstract]
2017	$ 1,664
2018	1,620
2019	1,644
Thereafter	554
Total	$ 5,482

Income Taxes - Summary of Significant Components of Provisions for Income Taxes Attributable to Operations (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2016

^[1]

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Current

International

$ (29)

$ (660)

Total current

(29)

(660)

Deferred

(14,630)

(681)

(1,360)

(15,311)

(1,360)

Total benefit from income taxes

$ (15,317)

$ (11)

$ (12)

$ (610)

$ (424)

$ (612)

$ (375)

$ (15,340)

$ (2,020)

[1]

These amounts reflect a benefit from income taxes after giving effect to the goodwill and deferred tax liability restatement discussed above. The impairment of the Company’s IPR&D in the quarter ended September 30, 2016 resulted in a benefit from income taxes of $15.3 million related to the reversal of the associated deferred tax liability in that quarter. The Company’s interim financial statements included in Form 10-Q for the quarter ended September 30, 2016 did not reflect this benefit from income taxes or the increase in impairment of goodwill.

Income Taxes - Schedule of Net Deferred Tax Asset (Liability) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal losses carryforward	$ 7,237	$ 90,121
Other tax credits	384	13,026
Scientific research and experimental development credit carryforward		3,460
State losses carryforward	371
Intangible assets	17,464
Stock compensation	1,726	1,167
Foreign deferrals		17,755
Inventory reserves		1,716
Fixed assets	160	1,357
Other	3,050	3,910
Deferred tax asset	30,392	132,512
Intangibles		(13,043)
Other	(575)	(797)
Deferred tax liability	(575)	(13,840)
Valuation allowance	$ (29,817)	(134,489)
Net deferred tax liabilities		$ (15,817)

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Federal net operating losses	$ 20,700,000	$ 257,400,000
State tax losses	10,500,000	0
Tax credits	400,000	13,200,000
Decrease in valuation allowance	(83,300,000)
Interest and penalties recognized	0
Foreign Country
Income Taxes [Line Items]
Canadian loss carryforwards	0	68,300,000
Foreign Country \| Research and Experimental
Income Taxes [Line Items]
Canadian scientific research and experimental development credits	$ 0	$ 3,500,000
Earliest Tax Year
Income Taxes [Line Items]
Operating losses, begin to expiration year	2037
Tax credits, begin to expiration year	2037

Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Reconciliation of unrecognized tax benefits [Roll Forward]
Increases (decreases) related to prior period tax positions	$ 76
Balance at the end of the year	$ 76

Income Taxes - Schedule of Benefit from Income Taxes Differs from Amount of Taxes Determined by Applying U.S. Federal Statuary Rate to Loss before Benefit from Income Taxes (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

^[1]

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Income Taxes [Line Items]

Loss before benefit from income taxes

$ (14,946)

$ (87,058)

$ (12,849)

$ (12,902)

$ (18,508)

$ (13,104)

$ (18,328)

$ (11,397)

$ (112,809)

$ (127,755)

$ (61,337)

Federal tax at statutory rates

(44,714)

(21,467)

State taxes, net of federal benefit

(1,189)

419

Impact of foreign operations

(29)

1,828

Change in valuation allowance

9,549

20,563

Separation related adjustment

11,055

Tax credits

(460)

(3,898)

Unrecognized tax benefits of tax credits

Permanent differences

10,372

535

Total benefit from income taxes

$ (15,317)

$ (11)

$ (12)

$ (610)

$ (424)

$ (612)

$ (375)

$ (15,340)

(15,340)

(2,020)

Income Taxes [Line Items]

Loss before benefit from income taxes

(123,199)

(41,648)

International

Income Taxes [Line Items]

Loss before benefit from income taxes

$ (4,556)

$ (19,689)

[1]

Selected Quarterly Financial Data (unaudited) - Additional Information (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Selected Quarterly Financial Data [Line Items]

Benefit from income taxes

$ 15,317

^[1]

$ 11

$ 12

$ 610

$ 424

$ 612

$ 375

$ 15,340

$ 2,020

Impairment of in process research and development costs

41,800

Total stockholders equity

97,197

89,862

88,618

$ 50,566

88,618

$ 94,608

Goodwill

29,213

Restatement Adjustment

Selected Quarterly Financial Data [Line Items]

Benefit from income taxes

$ 15,311

Total stockholders equity

Goodwill

$ 15,311

[1]

Selected Quarterly Financial Data (unaudited) - Balance Sheet Impact (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Goodwill		$ 29,213	$ 29,213	$ 29,213
Total assets	$ 91,858	133,470	127,916	127,767
Deferred income taxes		15,817	15,817	15,817
Total liabilities	41,292	36,273	38,054	39,149
Total stockholders equity	$ 50,566	97,197	89,862	88,618	$ 94,608
As Previously Reported
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Goodwill		13,902	13,902	13,902
Total assets		118,159	112,605	112,456
Deferred income taxes		506	506	506
Total liabilities		20,962	22,743	23,838
Total stockholders equity		97,197	89,862	88,618
Restatement Adjustment
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Goodwill		15,311	15,311	15,311
Total assets		15,311	15,311	15,311
Deferred income taxes		15,311	15,311	15,311
Total liabilities		15,311	15,311	15,311
Total stockholders equity		$ 0	$ 0	$ 0

Selected Quarterly Financial Data (unaudited) - Income Statement Impact (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Error Corrections And Prior Period Adjustments Restatement [Line Items]

Impairment expense

$ 71,013

Loss from operations

$ (14,553)

(86,565)

^[1]

$ (12,845)

$ (12,982)

$ (18,500)

$ (13,188)

$ (18,310)

$ (11,102)

(112,392)

(126,945)

$ (61,100)

Loss before income taxes

(14,946)

(87,058)

^[1]

(12,849)

(12,902)

(18,508)

(13,104)

(18,328)

(11,397)

(112,809)

(127,755)

(61,337)

Benefit from income taxes

15,317

^[1]

610

424

612

375

15,340

2,020

Net loss

$ (14,946)

(71,741)

^[1]

$ (12,838)

$ (12,890)

$ (17,898)

$ (12,680)

$ (17,716)

$ (11,022)

(97,469)

$ (112,415)

$ (59,317)

As Previously Reported

Error Corrections And Prior Period Adjustments Restatement [Line Items]

Impairment expense

55,702

Loss from operations

(71,254)

(97,081)

Loss before income taxes

(71,747)

(97,498)

Benefit from income taxes

Net loss

(71,741)

(97,469)

Restatement Adjustment

Error Corrections And Prior Period Adjustments Restatement [Line Items]

Impairment expense

15,311

Loss from operations

(15,311)

Loss before income taxes

(15,311)

Benefit from income taxes

$ 15,311

[1]

Selected Quarterly Financial Data (unaudited) - Unaudited Quarterly Consolidated Statement of Operations Data (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

^[1]

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Revenue

$ 8,769

$ 9,405

$ 10,193

$ 8,067

$ 8,286

$ 6,562

$ 7,090

$ 11,663

$ 36,434

$ 33,601

Loss from operations

(14,553)

(86,565)

(12,845)

(12,982)

(18,500)

(13,188)

(18,310)

(11,102)

$ (112,392)

(126,945)

(61,100)

Loss before income taxes

(14,946)

(87,058)

(12,849)

(12,902)

(18,508)

(13,104)

(18,328)

(11,397)

(112,809)

(127,755)

(61,337)

Benefit from income taxes

15,317

610

424

612

375

15,340

2,020

Net loss

$ (14,946)

$ (71,741)

$ (12,838)

$ (12,890)

$ (17,898)

$ (12,680)

$ (17,716)

$ (11,022)

$ (97,469)

$ (112,415)

$ (59,317)

Net loss per share - basic and diluted

$ (0.74)

$ (3.55)

$ (0.63)

$ (0.64)

$ (0.88)

$ (0.63)

$ (0.88)

$ (0.54)

$ (5.55)

$ (2.93)

[1]

Selected Quarterly Financial Data (unaudited) - Unaudited Quarterly Consolidated Statement of Operations Data (Parenthetical) (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Error Corrections And Prior Period Adjustments Restatement [Line Items]

Benefit from income taxes

$ 15,317

^[1]

$ 11

$ 12

$ 610

$ 424

$ 612

$ 375

$ 15,340

$ 2,020

Restatement Adjustment

Error Corrections And Prior Period Adjustments Restatement [Line Items]

Benefit from income taxes

$ 15,311

[1]

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 16. Subsequent Events On January 5, 2017, Aptevo received a $20.0 million payment that had been committed to by Emergent in the form of a promissory note at the closing of the spin-off.

Subsequent Events - Additional Information (Details) $ in Millions	Jan. 05, 2017 USD ($)
Subsequent Event \| Emergent \| Promissory Note
Subsequent Event [Line Items]
Cash funding committed by Emergent in connection with spin-off	$ 20.0

Inventories - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)
Inventory Adjustments [Abstract]
Inventory Write-down	$ 7.1